APA (7th ed.) Citation

Le, X., Sakai, H., Felip, E., Thomas, M., & Griesinger, F. (2022). Tepotinib efficacy and safety in patients with met exon 14 skipping nsclc: Outcomes in patient subgroups from the vision study with relevance for clinical practice. Clinical cancer research, 28(6), . https://doi.org/10.1158/1078-0432.CCR-21-2733

Chicago Style (17th ed.) Citation

Le, Xiuning, Hiroshi Sakai, Enriqueta Felip, Michael Thomas, and Frank Griesinger. "Tepotinib Efficacy and Safety in Patients with Met Exon 14 Skipping Nsclc: Outcomes in Patient Subgroups from the Vision Study with Relevance for Clinical Practice." Clinical Cancer Research 28, no. 6 (2022). https://doi.org/10.1158/1078-0432.CCR-21-2733.

MLA (9th ed.) Citation

Le, Xiuning, et al. "Tepotinib Efficacy and Safety in Patients with Met Exon 14 Skipping Nsclc: Outcomes in Patient Subgroups from the Vision Study with Relevance for Clinical Practice." Clinical Cancer Research, vol. 28, no. 6, 2022, https://doi.org/10.1158/1078-0432.CCR-21-2733.